United States Patent 9,994,576: Scope, Claim Coverage, and US Patent Landscape for BTK Inhibitor Compounds
US Patent 9,994,576 claims a core BTK inhibitor chemical scaffold defined by Formula (II) plus dependent claim narrowing, pharmaceutical compositions, and methods of use framed around Bruton’s tyrosine kinase (BTK) inhibition for autoimmune and inflammatory diseases and cancer. The claim set is structured to (i) cover broad structural latitude through Formula (II), (ii) lock down key sub-variants via specific Rc substituent classes, (iii) claim specific stereoisomeric embodiments (E and Z), and (iv) add composition and treatment claim coverage including idiopathic thrombocytopenic purpura (ITP) as an emphasized use case.
What is US Patent 9,994,576 actually claiming (Formula II, salts, and stereochemistry)?
Independent claim structure
- Claim 1 is the core. It claims a compound of Formula (II) plus pharmaceutically acceptable salts, where:
- Z is a defined linker/atom set (not fully visible in the excerpt, but Z is explicitly constrained).
- R1 and R2 are independently hydrogen, alkyl, halo, or alkoxy.
- R3 is hydrogen or halo.
- The critical variable is Rc, which is a substituent class that branches into multiple sub-classes (a) through (e).
Dependent claim narrowing
- Claims 2–6 narrow R2 (to alkyl/halo/alkoxy) and R3 (to fluoro), and narrow Rc to (a)-type piperazinyl embodiments.
- Claims 7–9 narrow the scaffold further to specific R1/R2 patterns (including R1 = H, R2 = H) and specify R3 = H or fluoro.
Composition claims
- Claim 10: pharmaceutical composition = excipient + compound of claim 1 (or salts).
- Claims 11–12: composition form is further limited to parenteral or oral.
Method-of-use claims (broad disease class)
- Claim 13: method of inhibiting BTK activity via administering a therapeutically effective amount of a claim 1 compound.
- Claim 14: provides a disease list under the autoimmune/inflammatory/cancer umbrella.
Specific exemplified chemical embodiments
- Claim 15 enumerates multiple named chiral and stereochemical compound identities, including:
- specific piperidinyl or pyrrolidinyl cores,
- substitution on the aryl ring (e.g., “2-fluoro” and “phenoxyphenyl” patterns),
- fixed “pent-2-enenitrile” motif,
- piperazine variants including oxetan-3-yl and 3-oxopiperazinyl substitution classes,
- and explicitly covers E/Z stereoisomer variants.
Further stereoisomer-specific claims
- Claims 19–20 separately claim:
- an (E) stereoisomer of the enumerated compounds (Claim 19),
- a (Z) stereoisomer of the enumerated compounds (Claim 20).
ITP emphasized claims
- Claims 21–22 claim methods to treat idiopathic thrombocytopenic purpura using:
- (R) or (S) oxetan-3-yl piperazinyl embodiments (Claim 21),
- or a mixture of (E) and (Z) stereoisomers of the listed (R)-oxetan-3-yl compound (Claim 22).
What does this claim architecture mean for scope?
- Chemical scope is broad at Formula (II) but is funnelled through Rc sub-classes, which operate like “entry gates.”
- Stereochemistry is not optional. The patent explicitly creates separate legal coverage for E and Z stereoisomers and for (R)/(S) chiral forms and certain mixtures.
- Use claims are broad by mechanism (BTK inhibition) and then enumerated by disease. This supports both:
- generic-style challenge framing (“no activity / wrong target” arguments), and
- infringement theories tied to label-indication or trial disease categories.
Which Rc substituent classes drive the claim breadth (and where are the tightest pinch points)?
Rc is defined through five mutually detailed branches in Claim 1:
-
Rc (a):
—C(CH3)2-(4-R5-piperazin-1-yl)
where R5 can be H, alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl.
The piperazinyl ring may be additionally substituted with one or two alkyl.
-
Rc (b):
—C(CH3)2-(2-oxo-4-Ra-piperazin-1-yl) or
—C(CH3)2-(3-oxo-4-Ra-piperazin-1-yl)
where Ra is H, alkyl, cycloalkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl.
Piperazinyl optionally bears one or two alkyl substituents.
-
Rc (c):
—C(CH3)2—NRb-oxetan-3-yl
where Rb is H, alkyl, hydroxyalkyl, alkoxyalkyl, or cycloalkyl.
-
Rc (d):
—C(CH3)2—Rd
where the substituent ring has a pattern where one or two of X1, X2, X3 are nitrogen (rest carbon), ring is optionally substituted with one or two substituents independently chosen from alkyl, haloalkyl, or halo.
-
Rc (e):
either
—C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl
or
—C(CH3)2—CH2-morpholin-4-yl.
Tightest legal chokepoints
- The dependent claims substantially emphasize Rc (a) with the 4-R5-piperazin-1-yl structure and particularly R5 = oxetan-3-yl.
- Claims 6 and 9 add R3 = fluoro, narrowing the halo pattern on the scaffold.
- Claims 19–20 and 21–22 are even narrower: they demand specific E/Z and specific enumerated structures consistent with the oxetan-3-yl piperazine embodiments.
How do claims 2–9 constrain the scaffold (R1, R2, R3) and what variants remain available?
R2 constraint (Claims 2 and 4)
- Claim 2: R2 is restricted to alkyl, halo, or alkoxy (eliminates hydrogen if treated as “independently,” but Claim 4’s Rc limitation reinforces particular Rc).
- Claim 4: adds Rc constraint to Rc = —C(CH3)2-(4-R5-piperazin-1-yl).
R3 constraint (Claims 3, 6, 9)
- Claim 3: R3 is fluoro.
- Claim 6: R3 is fluoro combined with Rc (a) constraint.
- Claim 9: same R1/R2 setup (from claim 7) but R3 = fluoro.
R1/R2 core narrowing (Claims 7–8)
- Claim 7 fixes: R1 = hydrogen; R2 = hydrogen and restricts Rc to the piperazinyl family.
- Claim 8 further specifies R3 = hydrogen.
Residual chemical freedom inside the legal boundary
Even with fixed R1/R2/R3, Rc permits multiple piperazine substituent patterns (R5 and optional alkyl substitutions on the piperazine ring). This means the patent is strong not only against a single compound, but against a family of close analogs that preserve the Rc linkage and target-binding motifs while varying substituents permitted by R5/Ra/Rb.
What compositions and dosage-form claims exist (oral vs parenteral coverage)?
- Claim 10: excipient + compound of claim 1 (or salt).
- Claim 11: composition is parenteral.
- Claim 12: composition is oral.
Infringement relevance
These claims track the typical “product formulation” strategy in US patent estates. If an ANDA applicant tries to enter with a compound that falls within claim 1 or claim 15 plus acceptable formulation, Claims 10–12 strengthen non-chemical infringement theories.
What method-of-use claims are asserted (BTK inhibition and disease lists)?
Mechanism
- Claims 13 and 17 cover “administering a therapeutically effective amount” of a claim 1 or claim 15 compound to inhibit BTK activity.
Disease class
- Claim 14 and Claim 18 list conditions spanning autoimmune/inflammatory disease and cancer-adjacent categories, including:
- rheumatoid arthritis
- psoriatic arthritis
- lupus
- uveitis
- myasthenia gravis
- warm autoimmune hemolytic anemia
- Wegener’s granulomatosis
- Sjogren’s disease and dry eye variants
- non-Sjogren’s dry eye disease
- psoriasis
- idiopathic thrombocytopenic purpura
- asthma
ITP-specific methods
- Claims 21–22 provide a dedicated ITP enforcement lane with chiral and stereoisomer scope.
Legal leverage
- If the compound is used in clinical protocols matching the enumerated diseases, the method claims can support infringement even with formulation differences.
- The ITP mixture claim (Claim 22) is particularly targeted for formulations or development programs using defined E/Z mixtures.
Which exact molecules are locked into the patent via Claim 15 (and how much is actually enumerated)?
Claim 15 explicitly enumerates multiple distinct stereochemical entities, including:
- a compound with a (3R) piperidine stereocenter and a piperazin-1-yl group substituted with phenoxyphenyl and a 2-fluoro aryl pattern,
- compounds with (R) and (S) variants on the piperidine or pyrrolidine core,
- compounds where the piperazine moiety is substituted by oxetan-3-yl or by 4-ethyl-3-oxopiperazinyl,
- plus explicit coverage of (E) or (Z) stereoisomer designations of the listed compounds.
Claim 15 acts like a “claim set anchor.”
Even though Claim 1 is broader, Claim 15 creates a second infringement pathway tied to specific enumerated structures that match common marketed-development exemplars for this scaffold family.
How do claims 19 and 20 separately claim the E and Z stereoisomers?
- Claim 19 covers (E) stereoisomer of the enumerated compound list of Claim 15.
- Claim 20 covers (Z) stereoisomer of the same enumerated set.
Practical impact for product design
A competitor attempting to argue non-infringement can be forced into an E/Z identity and mixture analysis. If the competitor supplies a mixture, Claim 22 (for ITP) explicitly claims an (E) and (Z) mixture for a defined (R)-oxetan-3-yl piperazinyl compound.
What patent landscape questions does this claim set naturally map to (composition, stereochemistry, method-of-use, and BTK target)?
Given only the excerpted claim text, the landscape analysis can be made at the level of what types of other patents typically coexist with this claim style. This patent’s structure indicates that in the US ecosystem, related estates commonly cluster into:
- Core scaffold patents (Formula-level claims like Claim 1).
- Substituent and homolog constraints (Rc/R5/Ra/Rb variations).
- Chirality patents (R/S embodiments).
- E/Z isomer patents and mixture composition patents.
- Formulation patents (oral vs parenteral).
- Method-of-use patents framed as BTK inhibition and specific autoimmune/inflammatory indications.
This claim set is internally consistent with a program where stereoisomers were developed and protected as separate enforceable entities.
How strong is the patent estate coverage based on the claim breadth shown here?
Strength indicators from the claim text alone:
- Broad chemical genus coverage through Formula (II) and Rc branching.
- Multiple narrowing dependent claims that reduce escape routes for “near-miss” analogs.
- Stereochemical specificity via E/Z and R/S embodiments.
- Use expansion: broad disease list plus ITP-specific dedicated claims.
This combination typically produces a litigation posture where a defendant has to defeat coverage at multiple layers: chemical structure, stereochemical form, and/or intended therapeutic use.
Key Takeaways
- US Patent 9,994,576 is a BTK inhibitor patent with Formula (II) chemical genus claims plus Rc sub-class-defined structural branches.
- The claim set is stereochemistry-aware: it separately claims E and Z stereoisomers and includes an E/Z mixture method claim for ITP.
- It covers not only compounds (claims 1 and 15) but also pharmaceutical compositions (oral and parenteral) and method-of-use (BTK inhibition across autoimmune/inflammatory diseases and cancer-related disease framing).
- The most enforceable pinch points are the constrained Rc piperazinyl/oxetan-3-yl and 3-oxo piperazinyl variants, plus R3 = fluoro and the E/Z and R/S enumerated embodiments.
FAQs
1. Does US 9,994,576 protect mixtures of E and Z stereoisomers?
Yes. Claim 22 expressly claims a mixture of (E) and (Z) stereoisomers for a defined (R)-oxetan-3-yl piperazinyl compound (plus salts).
2. Are oral and parenteral product formulations within the claim scope?
Yes. Claims 11 and 12 limit the composition claims to parenteral and oral forms.
3. Are method-of-use claims limited to a single indication like ITP?
No. The estate includes broad BTK inhibition method claims covering multiple autoimmune/inflammatory diseases (Claims 13–14 and 17–18) and then adds dedicated ITP claims (Claims 21–22).
4. What structural element in Claim 1 is most important for enforcing against close analogs?
The Rc substituent is the central structural branch that defines major piperazine/oxetan/spiro/morpholine variants.
5. Are E/Z stereoisomers protected only for specific enumerated compounds or for the full genus?
The E/Z claims (Claims 19–20) are directed to the enumerated compound list in Claim 15 rather than stating E/Z for the full Formula (II) genus in isolation.
References (APA)
- US Patent 9,994,576 (claims as provided in prompt).
